The University of Missouri is advancing its efforts against cancer by increasing the production of no-carrier-added lutetium-177 (NCA Lu-177). This radioisotope is a key component in innovative cancer treatments. Lutetium-177 is the active ingredient in Pluvicto and Lutathera, which are FDA-approved therapies for prostate cancer and neuroendocrine tumors, respectively. The University of Missouri Research Reactor (MURR) is currently the only producer of Lu-177 in the United States and started its initial production in fall 2023.
University President Mun Choi emphasized the importance of this expansion: “The growth and expansion at the University of Missouri Research Reactor is critical to the lives of so many cancer patients.” He noted that increased lutetium production would enable more life-saving treatments for patients nationwide.
Robin Wenneker, chair of the University Board of Curators, expressed pride in supporting this initiative: “The Board of Curators is proud to have approved this landmark initiative.” She added that it would enhance Missouri’s reputation as a leader in radiopharmaceuticals and cancer treatment.
Matt Sanford, MURR executive director, described this phase as “exciting” and foundational for future production capabilities. The expanded facilities will address rising demand as more radiopharmaceuticals gain FDA approval.
To support these efforts, agreements with radiopharmaceutical companies are essential. These partnerships aim to bolster domestic sources for critical radioisotopes. The university’s NextGen MURR project seeks to establish a new state-of-the-art reactor to further enhance research and treatment capabilities.
In 2023 alone, MURR’s radioisotopes contributed to treating over 1.6 million cancer and cardiac patients. The facility has been operational for nearly six decades, playing a crucial role not only within Missouri but also globally by providing essential resources for healthcare providers and researchers.
###
